Type Condition

Ventura, CA

200 Clinical Paid Trials near Ventura, CA

Power is an online platform that helps thousands of patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.

Learn More About Power
No Placebo
Highly Paid
Stay on Current Meds
Pivotal Trials (Near Approval)
Breakthrough Medication

Bimekizumab for Plaque Psoriasis

Santa Monica, California
The purpose of this study is to evaluate the effect of bimekizumab on gene expression biomarkers at Week 48 in a subset of study participants with moderate to severe plaque psoriasis (PSO) and moderate to severe plaque PSO with concomitant active psoriatic arthritis (PsA) who have provided skin biopsies for reverse transcription-polymerase chain reaction (RT-PCR).
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 3

90 Participants Needed

CCT-102 for Miscarriage

San Fernando, California
This trial is testing a treatment called CCT-102 to help women who have early pregnancies that stopped developing. The treatment aims to help clear the non-developing pregnancy tissue from their uterus. The study compares this treatment to simply waiting and monitoring the condition.
No Placebo Group
Pivotal Trial (Near Approval)

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18 - 50
Sex:Female

183 Participants Needed

Spironolactone vs Doxycycline for Acne

Sherman Oaks, California
This trial compares two treatments for women with moderate to severe acne. One treatment helps balance hormones to reduce skin oiliness, while the other kills bacteria and reduces inflammation. The goal is to see which treatment is more effective and potentially reduce the need for long-term antibiotic use.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 4
Age:16 - 40
Sex:Female

350 Participants Needed

RSV/hMPV Vaccine for Respiratory Syncytial Virus Immunization

Van Nuys, California
The aim of this study is to evaluate the safety and immunogenicity of a human metapneumovirus (hMPV) / respiratory syncytial virus (RSV) mRNA vaccine candidate encapsulated in a lipid nanoparticle (LNP) based formulation (hereafter referred to as hMPV/RSV vaccine) for the prevention of lower respiratory tract disease (LRTD) caused by hMPV and/or RSV among adults aged 60 years and older. Overall, the study is designed to address the following goals: * Assess the safety profile of the candidate formulations. * Describe the immunogenicity profile of the candidate formulations. * Select the vaccine formulations (dose) for future development. * Assess the safety and immunogenicity of a booster vaccination of the selected formulation administered 12 months after the primary vaccination in a subset of the study population. The study duration is as follows: -Six months each for the Sentinel and Main Cohorts; up to 12 months for the Expansion Cohort, and 12 additional months for the Booster Cohort Treatment duration: * Stage 1 Sentinel Cohort: 1 intra-muscular (IM) injection. Participants will be followed for 6 months post vaccination * Stage 1 Main Cohort: 1 IM injection. Participants will be followed for 6 months post vaccination * Stage 2 Expansion Cohort: 1 IM injection. Participants in the selected formulation arm will be followed for 12 months post-vaccination; the remainder of the participants will be followed for 8 months post-vaccination * Stage 2 Booster Cohort: 1 IM injection 12 months post-primary vaccination. Participants will be followed for 12 months post-booster vaccination

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:60+

1470 Participants Needed

Sotorasib for Solid Tumors

Santa Monica, California
Evaluate the safety and tolerability of sotorasib in adult subjects with KRAS p.G12C mutant advanced solid tumors. Estimate the maximum tolerated dose (MTD) and/or a recommended phase 2 dose (RP2D) in adult subjects with KRAS p.G12C mutant advanced solid tumors.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

713 Participants Needed

Trabectedin + Immunotherapy for Soft Tissue Sarcoma

Santa Monica, California
This is an open label, dose-seeking phase 1/2 study using escalating doses of TRABECTEDIN given intravenously with defined doses of IPILIMUMAB and NIVOLUMAB based on preliminary results of the Checkmate 012 trial for NSCLC (Hellman et al., 2016). For the Phase 1 Part of Study, only previously treated patients will be enrolled. For the Phase 2 Part of Study, previously treated patients will be enrolled.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

250 Participants Needed

Bria-OTS Immunotherapy for Breast Cancer

Santa Monica, California
This is an open-label Phase 1/2a study. Once the safety of the BC1 cell line alone has been demonstrated in Phase 1, in Phase 2, patients will be treated with the Bria-OTS regimen (see below) and a clinically available check point inhibitor (CPI). During the monotherapy phase of Phase 1, one patient will be treated intradermally every 2 weeks for 6 weeks (4 doses) with an initial dose of the BC1 cell line. If this dose is tolerated, the next patient will receive an increased dose of BC1. If once again tolerated, the third patient will receive a further dose increase of the BC1. Once at least 3 patients have been safely treated with the BC1 cell line, with no dose-limiting toxicity (DLT), the combinational phase of the study will commence. Following the monotherapy phase, patients will be treated with BC1 and the Bria-OTS regimen (see below) every 3 weeks, plus a CPI at the FDA approved labelled dose and schedule. There will be at least a 2-week spacing between enrollment of each of the first three subjects in the study in order to assess for any early unanticipated risk(s). During the Phase 1 combination and Phase 2 expansion phases, all patients will be treated with BC1 cells as part of the Bria-OTS regimen, which includes cyclophosphamide 300 mg/m2 2-3 days prior to BC1 cell inoculation, and peginterferon alpha-2a administered on the same day, following BC1 cell inoculation.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

18 Participants Needed

Lurbinectedin + Immunotherapy for Soft Tissue Sarcoma

Santa Monica, California
This is an open label, dose-seeking phase 1/2 study using escalating doses of LURBINECTEDIN administered intravenously with fixed doses of IPILIMUMAB and NIVOLUMAB administered intravenously.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

40 Participants Needed

SON-1010 + Atezolizumab for Ovarian Cancer

Santa Monica, California
This is a Phase 1b/2a, open-label, adaptive-design outpatient study to assess the safety, tolerability, and PK/PD of SON-1010 in combination with atezolizumab administered to patients with advanced solid tumors (Part 1) and patients with Platinum-resistant Ovarian Cancer (Part 2)
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

165 Participants Needed

XTX101 + Atezolizumab for Solid Cancers

Santa Monica, California
This is a first-in-human, Phase 1/2, multicenter, open-label study designed to evaluate the safety and tolerability of vilastobart (XTX101) as monotherapy and vilastobart (XTX101) and atezolizumab combination therapy in patients with advanced solid tumors.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

136 Participants Needed

AL3818 + Nivolumab for Cancer

Santa Monica, California
This trial is testing a new drug called AL3818 with Opdivo to treat patients with very advanced or returning cancers. AL3818 stops blood supply to tumors, while Opdivo helps the immune system attack cancer cells.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

56 Participants Needed

SQ3370 for Cancer

Santa Monica, California
The purpose of this study is to evaluate the safety, tolerability, and preliminary activity of SQ3370 in patients with advanced solid tumors.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

145 Participants Needed

APG-115 + Pembrolizumab for Skin Cancer

Santa Monica, California
This study aims to assess the safety, tolerability, pharmacokinetics, and preliminary efficacy of APG-115, an MDM2 inhibitor, either alone or in combination with pembrolizumab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with metastatic melanomas or advanced solid tumors. Our hypothesis is that restoration of the immune response concomitant to inhibition of the MDM2 pathway (which restores p53 functions) may promote cancer cell death, leading to effective anticancer therapy.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Age:12+

230 Participants Needed

Disitamab Vedotin for Breast Cancer

Van Nuys, California
The purpose of this clinical study is to learn about the safety and effects of the study medicine (called disitamab vedotin) for the possible treatment of people with breast cancer that is hard to treat and has spread in the body (advanced cancer). This study is seeking participants who: * have breast cancer that is hard to treat and has spread in the body (advanced cancer) * have tumors that have HER2 on them * have received previous treatment for their advanced breast cancer All participants in this study will receive disitamab vedotin at the study clinic once every 2 weeks as an intravenous (IV) infusion (given directly into a vein). Participants will take the study medicine until they or their doctor decides to stop. This might be because their cancer is getting worse, the study medicine is no longer helping, they have bad side effects, or they wish to stop taking the study medicine. During this time, the participants will have study visits every 2 weeks. After the participants have stopped taking the study medicine, they will have follow-up visits about every 6 weeks unless their cancer gets worse. After that, they will have follow-up phone calls about every 12 weeks. The study team will look at the experiences of people receiving the study medicine. This will help the study team decide if the study medicine is safe and effective.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

100 Participants Needed

INCB177054 + Retifanlimab for Solid Tumors

Panorama City, California
This study will be conducted to evaluate INCB177054 given as monotherapy or in combination with retifanlimab in participants with select advanced or metastatic solid Tumors.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

322 Participants Needed

M9140 for Solid Tumors

Santa Monica, California
The PROCEADE PanTumor study aims to investigate M9140 in multiple tumor types which express carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and it is therefore designed as a matrix study. This study aims to assess the antitumor activity, tolerability, safety, and pharmacokinetics (PK) of M9140 as monotherapy or in combination treatments in adult participants with locally advanced/metastatic CEACAM5 expressing tumors. There will be 3 substudies under this Master Protocol that may be conducted in parallel. * PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants with Advanced Gastric Cancer (Substudy GC); * PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants with Advanced Non-Small Cell Lung Cancer (Substudy NSCLC); * PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Pancreatic Cancer (Substudy PDAC).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

250 Participants Needed

Patritumab Deruxtecan for Gastrointestinal Cancer

Santa Monica, California
Researchers want to learn if patritumab deruxtecan (MK-1022) can treat certain gastrointestinal (GI) cancers. The GI cancers being studied are advanced (the cancer has spread to other parts of the body). The goals of this study are to learn: * About the safety and how well people tolerate of patritumab deruxtecan * How many people have the cancer respond (get smaller or go away) to treatment
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

130 Participants Needed

RYZ101 Alone and with Pembrolizumab for Breast Cancer

Santa Monica, California
Phase 1b/2 open-label trial of 225Ac-DOTATATE (RYZ101) in subjects with ER+, HER2-negative unresectable or metastatic breast cancer expressing SSTRs.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

124 Participants Needed

AT-1965 for Cancer

Santa Monica, California
This is a first-in-human, multicenter, open-label, dose escalation and dose expansion Phase 1/2 study to determine the MTD and/or the recommended Phase 2 dose (RP2D) and to characterize DLTs of AT-1965 as well as to investigate the safety, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of AT-1965 in patients with advanced, refractory or recurrent solid tumors (nonresectable and/or metastatic) including mTNBC.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

85 Participants Needed

DB-1311 for Advanced Cancer

Santa Monica, California
This trial tests a new drug, DB-1311, in patients with advanced solid tumors. It aims to find the safest and most effective dose and then confirm its safety and effectiveness in more patients.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

610 Participants Needed

Why Other Patients Applied

"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."

IZ
Healthy Volunteer PatientAge: 38

"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."

ZS
Depression PatientAge: 51

"I changed my diet in 2020 and I’ve lost 95 pounds from my highest weight (283). I am 5’3”, female, and now 188. I still have a 33 BMI. I've been doing research on alternative approaches to continue my progress, which brought me here to consider clinical trials."

WR
Obesity PatientAge: 58

"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."

HZ
Arthritis PatientAge: 78

"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."

AG
Paralysis PatientAge: 50

AR-14034 for Age-Related Macular Degeneration

Encino, California
The primary purpose of this study is to evaluate the safety and durability of single- and repeat administration of AR-14034 Sustained Release (SR) in subjects with neovascular age-related macular degeneration (nAMD).
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:50+

140 Participants Needed

Lonigutamab for Thyroid Eye Disease

Beverly Hills, California
This trial is testing a new medication called lonigutamab to help people with Thyroid Eye Disease (TED). TED causes eye problems due to thyroid issues. Lonigutamab may work by reducing inflammation and other symptoms in the eyes.

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

54 Participants Needed

IMM-1-104 for Solid Cancers

Santa Monica, California
This trial is testing a new drug called IMM-1-104 to see if it can help treat advanced cancers with specific genetic changes. The drug works by blocking signals that make cancer cells grow.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

320 Participants Needed

YH001 + Envafolimab for Sarcoma

Santa Monica, California
This is a multicenter, open label, Phase 1/2 study of YH001 initially given in combination with envafolimab, and then given in combination with envafolimab plus doxorubicin in patients with advanced or metastatic sarcoma, followed by Phase 2 cohorts of patients with select histologies of advanced or metastatic sarcoma.
No Placebo Group

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

15 Participants Needed

Seclidemstat Access for Sarcoma

Santa Monica, California
This trial allows patients who have previously benefited from seclidemstat to continue their treatment. Seclidemstat is a drug that aims to stop cancer cells from growing by blocking essential proteins. The trial targets patients who are still seeing positive results.
No Placebo Group

Trial Details

Trial Status:Enrolling By Invitation
Trial Phase:Phase 1, 2
Age:12+

10 Participants Needed

NGM707 + Pembrolizumab for Cancer

Santa Monica', California
This trial is testing a new drug called NGM707, both by itself and with another drug, Pembrolizumab. It targets patients with very advanced or spreading solid tumors. The treatment aims to boost the immune system to better fight cancer.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

179 Participants Needed

Pembrolizumab Combinations for Melanoma

Santa Monica, California
Substudy 02D is part of a larger research study that is testing experimental treatments for melanoma, a type of skin cancer. The larger study is the umbrella study. The goal of substudy 02D is to evaluate the safety and efficacy of investigational treatment arms in programmed cell-death 1 (PD-1) naïve or PD-1 exposed participants with melanoma brain metastasis (MBM) and to identify the investigational agent(s) that, when used in combination, are superior to the current treatment options/historical control available. As of amendment 2 (effective 01DEC2022) enrollment into the treatment arm of pembrolizumab and lenvatinib has been discontinued.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

300 Participants Needed

Zifibancimig for Age-Related Macular Degeneration

Encino, California
This trial is testing a new treatment called zifibancimig for people with a serious eye condition known as neovascular age-related macular degeneration (nAMD). The treatment is given either as an injection into the eye or through a small implant. It works by stopping harmful blood vessels from growing in the eye, which can help protect or improve vision.
No Placebo Group

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:50+

251 Participants Needed

Immunotherapy Combinations for Advanced Liver Cancer

Santa Monica, California
This is a Phase Ib/II, open-label, multicenter, randomized umbrella study in participants with advanced liver cancers. The study is designed with the flexibility to open new treatment arms as new treatments become available, close existing treatment arms that demonstrate minimal clinical activity or unacceptable toxicity, modify the participant population, or introduce additional cohorts of participants with other types of advanced primary liver cancer. Cohort 1 will enroll participants with locally advanced or metastatic hepatocellular carcinoma (HCC) who have not received prior systemic therapy for their disease. Eligible participants will initially be randomly assigned to one of several treatment arms (Stage 1). Participants who experience loss of clinical benefit or unacceptable toxicity during Stage 1 may be eligible to receive treatment with a different treatment combination (Stage 2). When a Stage 2 treatment combination is available, this will be introduced by amending the protocol.
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Recruiting
Trial Phase:Phase 1, 2

518 Participants Needed

Pembrolizumab Combinations for Melanoma

Santa Monica, California
Substudy 02B is part of a larger research study where researchers are looking for new ways to treat advanced melanoma that has not been treated before. The larger study is the umbrella study. Researchers want to know if adding other treatments to pembrolizumab can treat advanced melanoma. The goals of this study are to learn: * About the safety and how well people tolerate pembrolizumab given with other treatments * How many people have melanoma that responds (gets smaller or goes away) to treatment
No Placebo Group
Prior Safety Data

Trial Details

Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2

315 Participants Needed

1234...7

Know someone looking for new options? Spread the word

Learn More About Power

Why We Started Power

We started Power when my dad was diagnosed with multiple myeloma, and I struggled to help him access the latest immunotherapy. Hopefully Power makes it simpler for you to explore promising new treatments, during what is probably a difficult time.

Bask
Bask GillCEO at Power
Learn More About Trials
How Do Clinical Trials Work?Are Clinical Trials Safe?What Can I Expect During a Clinical Trial?

Frequently Asked Questions

How much do clinical trials in Ventura, CA pay?

Each trial will compensate patients a different amount, but $50-100 for each visit is a fairly common range for Phase 2–4 trials (Phase 1 trials often pay substantially more). Further, most trials will cover the costs of a travel to-and-from the clinic.

How do clinical trials in Ventura, CA work?

After a researcher reviews your profile, they may choose to invite you in to a screening appointment, where they'll determine if you meet 100% of the eligibility requirements. If you do, you'll be sorted into one of the treatment groups, and receive your study drug. For some trials, there is a chance you'll receive a placebo. Across trials in Ventura, CA 30% of clinical trials have a placebo. Typically, you'll be required to check-in with the clinic every month or so. The average trial length in Ventura, CA is 12 months.

How do I participate in a study as a "healthy volunteer"?

Not all studies recruit healthy volunteers: usually, Phase 1 studies do. Participating as a healthy volunteer means you will go to a research facility in Ventura, CA several times over a few days or weeks to receive a dose of either the test treatment or a "placebo," which is a harmless substance that helps researchers compare results. You will have routine tests during these visits, and you'll be compensated for your time and travel, with the number of appointments and details varying by study.

What does the "phase" of a clinical trial mean?

The phase of a trial reveals what stage the drug is in to get approval for a specific condition. Phase 1 trials are the trials to collect safety data in humans. Phase 2 trials are those where the drug has some data showing safety in humans, but where further human data is needed on drug effectiveness. Phase 3 trials are in the final step before approval. The drug already has data showing both safety and effectiveness. As a general rule, Phase 3 trials are more promising than Phase 2, and Phase 2 trials are more promising than phase 1.

Do I need to be insured to participate in a medical study in Ventura, CA?

Clinical trials are almost always free to participants, and so do not require insurance. The only exception here are trials focused on cancer, because only a small part of the typical treatment plan is actually experimental. For these cancer trials, participants typically need insurance to cover all the non-experimental components.

What are the newest clinical trials in Ventura, CA?

Most recently, we added Fecal Microbiota Transplant for Parkinson's Disease, Niraparib + Temozolomide for Small Cell Lung Cancer and Tazemetostat + PD-1 Blockade for Non-Small Cell Lung Cancer to the Power online platform.

Popular Searches

By Condition

Depression Clinical Trials in California

Anxiety Clinical Trials in California

Schizophrenia Clinical Trials in California

ADHD Clinical Trials in California

Bipolar Disorder Clinical Trials in California

Multiple Sclerosis Clinical Trials in California

Autism Clinical Trials in California

Treatment Resistant Depression Clinical Trials in California

Borderline Personality Disorder Clinical Trials in California

Social Anxiety Disorder Clinical Trials in California

Parkinson's Disease Clinical Trials in California

Alzheimer's Disease Clinical Trials in California

By Location

Clinical Trials near Los Angeles, CA

Clinical Trials near San Francisco, CA

Clinical Trials near San Diego, CA

Clinical Trials near Sacramento, CA

Clinical Trials near La Jolla, CA

Clinical Trials near Orange, CA

Clinical Trials near Stanford, CA

Clinical Trials near Palo Alto, CA

Clinical Trials near Long Beach, CA

Clinical Trials near Duarte, CA

Clinical Trials near Oakland, CA

Clinical Trials near Santa Monica, CA

Other People Viewed

By Subject

Top Clinical Trials near Ventura, CA

Top Depression Clinical Trials near Ventura, CA

Top Colorectal Cancer Clinical Trials near Ventura, CA

Top Lung Cancer Clinical Trials near Ventura, CA

Top Breast Cancer Clinical Trials near Ventura, CA

Top Prostate Cancer Clinical Trials near Ventura, CA

19 Weight Loss Trials near Ventura, CA

Top Clinical Trials near Chino, CA

Top Clinical Trials near Carlsbad, CA

Top Clinical Trials near Auburn, CA

Top Clinical Trials near Alhambra, CA

Top Clinical Trials near Anaheim, CA

By Trial

Caregiver Support Technology for Dementia

tDCS for Cognitive Impairment After Stroke

Vorinostat + Ustekinumab for Crohn's Disease

Digital Messaging Interventions for Physical Activity Promotion

Hyaluronidase for Muscle Spasms

Metreleptin for Partial Lipodystrophy

Nitrate Supplementation for Vascular Health in Diverse Populations

Home-Based Infant Behavior Intervention for Behavioral Problems

Intramuscular Epinephrine for Out-of-Hospital Cardiac Arrest

A Study to Test if TEV-48574 is Effective in Relieving Asthma

AZD5148 for Healthy Subjects

Hypofractionated Radiotherapy for Cancer

Related Searches

Top Clinical Trials near Colorado

Top Clinical Trials near Massachusetts

Neurostimulation and Motor Training for Spinal Cord Injury

Fecobionics Device for Chronic Constipation

Electrical Stimulation for Spinal Cord Injury

LY4268989 for Healthy Subjects

Bronchodilator Therapy for Cystic Fibrosis

Exablate Prostate Treatment for Prostate Cancer

CCM Therapy for Heart Failure

Psilocybin for ALS

Enhanced Home Rehabilitation Therapy for Elderly Care

Venetoclax + Azacitidine for Leukemia

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security
Match to a Trial